Real-World Study of DLBCL With Different Genetic Subtypes

Launched by RUIJIN HOSPITAL · Sep 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a type of cancer called Diffuse Large B Cell Lymphoma (DLBCL). The goal is to gather information about how well different treatments work for patients with various genetic subtypes of DLBCL. Researchers want to understand the effectiveness, safety, and overall survival of these treatments in real-world settings, meaning they will be looking at patients as they are treated in everyday medical practice.

If you or a loved one has been diagnosed with DLBCL and is between the ages of 65 and 74, you may be eligible to participate in this trial. To qualify, you must have a confirmed diagnosis of DLBCL and have one of the specific genetic subtypes identified through a test. Participants will be asked to give their consent to join the study, and they will need to agree to use reliable contraception if applicable. Throughout the study, participants can expect to receive the usual care for their condition while contributing to valuable research that may help improve treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
• • Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
• • Fully comprehension and signature of the informed consent form (ICF) for participation
• Exclusion Criteria:
• • Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
• • Severe mental illness
• • Patients deemed unsuitable for inclusion by the investigator